Table 3.
The associations of eGFRcystatin C/eGFRcreatinine ratio with baPWV ≥1,550 cm/sec and carotid plaque
| eGFRcystatin C/eGFRcreatinine ratio | OR (95% CI) | ||
|---|---|---|---|
|
| |||
| <0.9 | 0.9–1.1 (Reference) | >1.1 | |
| baPWV ≥1,550 cm/sec | |||
| Unadjusted | 2.34 (1.34–4.03) | 1 | 0.72 (0.51–1.01) |
| Model 1 | 2.44 (1.28–4.66) | 1 | 0.83 (0.55–1.25) |
| Model 2 | 2.54 (1.29–5.01) | 1 | 0.82 (0.54–1.26) |
|
| |||
| Carotid plaque | |||
| Unadjusted | 2.25 (1.23–4.00) | 1 | 0.76 (0.50–1.15) |
| Model 1 | 2.12 (1.13–3.98) | 1 | 0.85 (0.54–1.33) |
| Model 2 | 1.95 (1.02–3.71) | 1 | 0.90 (0.56–1.44) |
Model 1: adjusted for age, sex, body mass index, hypertension, duration of diabetes, and glycosylated hemoglobin; Model 2: adjusted for Model 1+pulse pressure, antiplatelet therapy, intima-media thickness, ankle-brachial index, total cholesterol, high-density lipoprotein cholesterol, and uric acid.
eGFR, estimated glomerular filtration rate; baPWV, brachial-ankle pulse wave velocity; OR, odds ratio; CI, confidence interval.